Charles River Laboratories International (CRL) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 27, 2026
- EPS actual
- $3.02
- EPS estimate
- $2.74
- EPS surprise
- +10.13%
- Revenue surprise
- +2.75%
- Revenue
- $1.0B
- Revenue estimate
- $977.2M
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $2.74 | $3.02 | +10.13% | $1.0B | SEC |
| Q1 2026 | May 7, 2026 | $1.94 | $2.06 | +6.00% | $995.8M | SEC |
| Q4 2025 | Feb 18, 2026 | $2.34 | $2.39 | +1.98% | $994.2M | SEC |
| Q3 2025 | Nov 5, 2025 | $2.34 | $2.43 | +3.95% | $1.0B | SEC |
| Q2 2025 | Aug 6, 2025 | $2.50 | $3.12 | +24.69% | $1.0B | SEC |
| Q1 2025 | May 7, 2025 | $2.08 | $2.34 | +12.73% | $984.2M | SEC |
| Q4 2024 | Feb 19, 2025 | $2.53 | $2.66 | +5.24% | $1.0B | SEC |
| Q3 2024 | Nov 6, 2024 | $2.42 | $2.59 | +6.91% | $1.0B | SEC |
| Q2 2024 | Aug 7, 2024 | $2.39 | $2.80 | +16.95% | $1.0B | SEC |
| Q1 2024 | May 9, 2024 | $2.06 | $2.27 | +9.93% | $1.0B | SEC |
| Q4 2023 | Feb 14, 2024 | $2.40 | $2.46 | +2.42% | $1.0B | SEC |
| Q3 2023 | Nov 8, 2023 | $2.36 | $2.72 | +15.40% | $1.0B | SEC |
| Q2 2023 | Aug 9, 2023 | $2.64 | $2.69 | +1.96% | $1.1B | SEC |
| Q1 2023 | May 11, 2023 | $2.59 | $2.78 | +7.40% | $1.0B | SEC |
| Q4 2022 | Feb 22, 2023 | $2.75 | $2.98 | +8.55% | $1.1B | SEC |
| Q3 2022 | Nov 2, 2022 | $2.50 | $2.63 | +5.09% | $989.2M | — |
| Q2 2022 | Aug 3, 2022 | $2.74 | $2.77 | +1.16% | $973.1M | — |
| Q1 2022 | May 4, 2022 | $2.72 | $2.75 | +1.18% | $913.9M | — |
| Q4 2021 | Feb 16, 2022 | $2.43 | $2.49 | +2.38% | $905.0M | — |
| Q3 2021 | Nov 3, 2021 | $2.58 | $2.70 | +4.48% | $895.9M | — |
Quarterly revenue
Frequently asked questions
When did Charles River Laboratories International (CRL) last report earnings?
Charles River Laboratories International last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did CRL beat earnings estimates?
Yes. Charles River Laboratories International reported EPS of $3.02 for Q2 2026 against a $2.74 estimate — a 10.13% beat.
How much revenue did CRL report last quarter?
Charles River Laboratories International reported $1.0B in revenue for Q2 2026, against a consensus estimate of $977.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.